← Return to ADT and rising PSA

Discussion
mjp0512 avatar

ADT and rising PSA

Prostate Cancer | Last Active: Jul 16 1:26pm | Replies (58)

Comment receiving replies
Profile picture for Jeff Marchi @jeffmarc

@surftohealth88 @mjp0512
That is a real nice drop after RT. When I had my L4 zapped, I dropped from .2 to undetectable in 1.5 months. I was on Orgovyx and nebeqa at the time. He started at a much higher number.

After radiation, PSA can bounce around a little bit, And for some people, it can take a long time to drop To the lowest level they will reach. I’d want to see his results in another month it may continue to go down and chemo may not be necessary.

The important thing is What was found in the PSMA PET scan. Was it just that one spot on L5? For that, they would not normally set up chemo.

Jump to this post


Replies to "@surftohealth88 @mjp0512 That is a real nice drop after RT. When I had my L4 zapped,..."

@jeffmarc - Hi Jeff...only other thing noted on last PSMA PET was increase in uptake on one side of the prostate. RO said lingering effects and could take 9 mos to a year to show improvement after IMRT in October 2025. GUO did not address it before he retired hence new GUO contacted, we'll see what he says. At least L5 got zapped and I don't hurt anymore. Also, lymph systems uptakes have all vanished so that's pretty cool.

Findings: PSMA PET 4/30/2026

Neck: No suspicious tracer avid disease.

Chest: No suspicious tracer avid disease.

Abdomen/Pelvis: Fiducial markers in the prostate gland. Increased focal tracer activity in the RIGHT apical prostate adjacent to a fiducial marker, max SUV 19.3, previously 11.1. Decreased tracer activity in the LEFT apical prostate, max SUV 7.8, previously 10.0.

Interval resolution of tracer avid metastatic lymphadenopathy in the pelvis, retroperitoneum, and mediastinum.

Bones: Increased tracer activity associated with sclerotic lesion in the L5 vertebral body, current max SUV 17.5, previously 11.9. Increased sclerosis since prior study. No new tracer avid osseous lesions identified.